Toroso Investments LLC Buys Shares of 1,726 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Toroso Investments LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,726 shares of the medical equipment provider’s stock, valued at approximately $266,000.

A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of Zimmer Biomet by 23.9% during the fourth quarter. BlackRock Inc. now owns 19,395,694 shares of the medical equipment provider’s stock valued at $2,988,683,000 after purchasing an additional 3,738,953 shares in the last quarter. Viking Global Investors LP raised its stake in shares of Zimmer Biomet by 128.8% during the fourth quarter. Viking Global Investors LP now owns 3,867,074 shares of the medical equipment provider’s stock valued at $595,877,000 after purchasing an additional 2,176,989 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Zimmer Biomet by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 2,023,426 shares of the medical equipment provider’s stock valued at $311,792,000 after purchasing an additional 41,605 shares in the last quarter. Ceredex Value Advisors LLC raised its stake in shares of Zimmer Biomet by 38.7% during the fourth quarter. Ceredex Value Advisors LLC now owns 1,455,992 shares of the medical equipment provider’s stock valued at $224,701,000 after purchasing an additional 406,268 shares in the last quarter. Finally, FIL Ltd raised its stake in shares of Zimmer Biomet by 47.1% during the fourth quarter. FIL Ltd now owns 899,868 shares of the medical equipment provider’s stock valued at $138,660,000 after purchasing an additional 288,310 shares in the last quarter. Institutional investors own 87.17% of the company’s stock.

Shares of ZBH opened at $161.32 on Friday. The company has a current ratio of 2.18, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Zimmer Biomet Holdings, Inc. has a 1-year low of $88.00 and a 1-year high of $170.05. The business’s 50-day moving average price is $160.11 and its 200 day moving average price is $150.42. The stock has a market capitalization of $33.61 billion, a P/E ratio of 1,008.31, a P/E/G ratio of 4.32 and a beta of 1.34.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 4th. The medical equipment provider reported $2.11 EPS for the quarter, topping the consensus estimate of $2.06 by $0.05. The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.08 billion. Zimmer Biomet had a net margin of 0.52% and a return on equity of 10.07%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company posted $2.30 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 4.8 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 30th. Shareholders of record on Monday, March 29th will be given a $0.24 dividend. The ex-dividend date is Friday, March 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.60%. Zimmer Biomet’s payout ratio is 12.20%.

A number of equities research analysts recently weighed in on ZBH shares. The Goldman Sachs Group upgraded shares of Zimmer Biomet from a “buy” rating to a “conviction-buy” rating in a research note on Tuesday, December 15th. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating and set a $167.00 price target on the stock. in a research report on Wednesday, February 10th. Piper Sandler boosted their price target on shares of Zimmer Biomet from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, February 5th. JMP Securities boosted their price target on shares of Zimmer Biomet from $165.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 27th. Finally, Needham & Company LLC boosted their price target on shares of Zimmer Biomet from $185.00 to $192.00 and gave the stock a “strong-buy” rating in a research report on Friday, February 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Buy” and an average price target of $165.65.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.

Read More: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.